12166 related articles for article (PubMed ID: 10586378)
21. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.
Leithäuser F; Dhein J; Mechtersheimer G; Koretz K; Brüderlein S; Henne C; Schmidt A; Debatin KM; Krammer PH; Möller P
Lab Invest; 1993 Oct; 69(4):415-29. PubMed ID: 7693996
[TBL] [Abstract][Full Text] [Related]
22. Expression in childhood primary brain tumors of NY-ESO-1, a cancer/testis antigen: an immunohistochemical study.
Bodey B; Bodey V; Siegel SE
In Vivo; 2008; 22(1):83-7. PubMed ID: 18396787
[TBL] [Abstract][Full Text] [Related]
23. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
24. Expression of Fas/APO-1 during the progression of astrocytomas.
Tachibana O; Nakazawa H; Lampe J; Watanabe K; Kleihues P; Ohgaki H
Cancer Res; 1995 Dec; 55(23):5528-30. PubMed ID: 7585627
[TBL] [Abstract][Full Text] [Related]
25. Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells.
Zhang J; Xu G
Cancer Genet Cytogenet; 2007 Dec; 179(2):112-7. PubMed ID: 18036397
[TBL] [Abstract][Full Text] [Related]
26. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells.
Naujokat C; Sezer O; Possinger K
Biochem Biophys Res Commun; 1999 Nov; 264(3):813-9. PubMed ID: 10544014
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis and Fas-ligand expression correlate to the histopathological grade of gastric smooth muscle tumors.
Liu Y; Chen C; Chen C; Hsieh H; Chang C; Shyu J; Yen C; Harn H
J Surg Res; 2001 Feb; 95(2):92-8. PubMed ID: 11162031
[TBL] [Abstract][Full Text] [Related]
29. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
30. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.
Rempel SA; Dudas S; Ge S; Gutiérrez JA
Clin Cancer Res; 2000 Jan; 6(1):102-11. PubMed ID: 10656438
[TBL] [Abstract][Full Text] [Related]
31. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(3A):1759-68. PubMed ID: 10928105
[TBL] [Abstract][Full Text] [Related]
32. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover.
French LE; Tschopp J
Behring Inst Mitt; 1996 Oct; (97):156-60. PubMed ID: 8950473
[TBL] [Abstract][Full Text] [Related]
33. Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3.
Ray SK; Patel SJ; Welsh CT; Wilford GG; Hogan EL; Banik NL
J Neurosci Res; 2002 Jul; 69(2):197-206. PubMed ID: 12111801
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis-related proteins (Fas, Fas ligand, bcl-2 and p53) in different types of human breast tumors.
Ben-Hur H; Mordechay E; Halperin R; Gurevich P; Zandbank J; Herper M; Zusman I
Oncol Rep; 2002; 9(5):977-80. PubMed ID: 12168058
[TBL] [Abstract][Full Text] [Related]
35. CD44 expression in astrocytic tumors.
Ylagan LR; Quinn B
Mod Pathol; 1997 Dec; 10(12):1239-46. PubMed ID: 9436970
[TBL] [Abstract][Full Text] [Related]
36. Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma.
Gross N; Balmas K; Beretta Brognara C; Tschopp J
Med Pediatr Oncol; 2001 Jan; 36(1):111-4. PubMed ID: 11464860
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications.
Navarro S; Giraudo P; Karseladze AI; Smirnov A; Petrovichev N; Savelov N; Alvarado-Cabrero I; Llombart-Bosch A
Anticancer Res; 2007; 27(4B):2457-63. PubMed ID: 17695539
[TBL] [Abstract][Full Text] [Related]
38. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
39. Expression and function of the murine CD95/FasR/APO-1 receptor in relation to B cell ontogeny.
Onel KB; Tucek-Szabo CL; Ashany D; Lacy E; Nikolic-Zugic J; Elkon KB
Eur J Immunol; 1995 Oct; 25(10):2940-7. PubMed ID: 7589095
[TBL] [Abstract][Full Text] [Related]
40. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
